Bavarian Nordic AS

Latest Results (11.10.2025):

Bavarian Nordic AS reported a strong performance in the first quarter of 2025, achieving a 62% increase in revenue to DKK 1,347 million. The company's growth was driven by significant advancements in both its Travel Health and Public Preparedness segments. Operating profit reached DKK 420 million, and the company maintained its full-year financial guidance.

Revenue Growth

The first quarter of 2025 saw Bavarian Nordic AS's revenue surge by 62% to DKK 1,347 million compared to the same period in 2024. This growth was primarily fueled by a 52% increase in Travel Health revenue and an impressive 83% rise in Public Preparedness revenue.

Operating Profit

The company's operating profit (EBITDA) for the quarter was DKK 420 million, reflecting an EBITDA margin of 31%. This significant improvement underscores the effective cost management and robust sales performance during the period.

Financial Guidance

Bavarian Nordic AS has maintained its financial guidance for the full year 2025, projecting revenue between DKK 5,700 million and DKK 6,700 million, with an EBITDA margin ranging from 26% to 30%. This outlook demonstrates the company's confidence in sustaining its growth trajectory.

Strategic Developments

The company successfully launched Vimkunya, its chikungunya vaccine, in the US and is on track for a European rollout. Additionally, Bavarian Nordic secured a Priority Review Voucher and entered a strategic partnership with Biological E. Limited to enhance vaccine supply capabilities for low- and middle-income countries.

Public Preparedness Achievements

Public Preparedness revenue exceeded expectations with an 83% increase, driven by advanced deliveries of mpox/smallpox vaccines. The approval of the freeze-dried JYNNEOS vaccine by the FDA supports ongoing contracts for government stockpiling, reinforcing the company's position in public health preparedness.